Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Non-Muscle Invasive Urothelial Carcinoma
Latest News
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Dr. Neal Shore discusses how the investigational treatment TARA-002 can aid patients during the ongoing BCG shortage.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Karine Tawagi and Samantha Armstrong expand on the prostate cancer discussions of note, including TALAPRO-2.
Drs. Tawagi and Armstrong provide detail and discussion on the bladder cancer research from the 2025 ASCO GU meeting.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
Dr. Sonpavde provides an update on the latest analysis from the phase 3 global study of EV in combination with pembro.
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.